氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的效果观察

Efficacy of amlodipine atorvastatin calcium in the treatment of hypertension patients complicated with coronary heart disease

目的观察氨氯地平阿托伐他汀钙治疗高血压合并冠心病的效果。方法 114例高血压合并冠心病患者随机分为对照组和研究组,每组57例。对照组采用阿托伐他汀治疗,研究组采用氨氯地平阿托伐他汀钙治疗,比较两组的收缩压、舒张压、血脂水平、疗效以及不良反应发生情况。结果治疗前两组的收缩压、舒张压水平差异无统计学意义(P>0.05),治疗后研究组均低于对照组(P<0.01)。治疗前两组的甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白(LDL-C)及高密度脂蛋白(HDL-C)水平差异无统计学意义(P>0.05),治疗后研究组的TG、TC、LDL-C均优于对照组(P<0.01或0.05)。研究组疗效优于对照组(P<0.01)。两组的不良反应发生率差异无统计学意义(5.26%vs 8.77%,P>0.05)。结论氨氯地平阿托伐他汀钙治疗高血压合并冠心病效果明显,能有效改善血压、血脂水平,控制疾病发展。

Objective To observe the efficacy of amlodipine atorvastatin calcium in the treatment of hypertension patients complicated with coronary heart disease(CHD). Methods A total of 114 hypertension patients complicated with CHD were selected and randomly divided into two groups, 57 cases in each group. The Control Group was treated with atorvastatin while the Study Group was treated with amlodipine atorvastatin calcium. The systolic blood pressure(SBP), diastolic blood pressure(DBP), blood lipid level, therapeutic effect and the incidence of adverse reactions were compared between the two groups. Results The SBP and DBP level of the two groups had no statistical difference before the treatment(P>0.05), but the SBP and DBP level of the Study Group were lower than those of the Control Group after the treatment(P<0.05). The triglyceride(TG), total cholesterol(TC), low-density lipoprotein cholesterol(LDL-C) and high-density lipoprotein cholesterol(HDL-C) of the two groups had no statistical difference before the treatment(P>0.05), but those of the Study Group were superior to those of the Control Group after the treatment(P<0.01 or 0.05). The Study Group had the therapeutic efficacy superior to the Control Group(P<0.01). There was no statistical difference in the incidence of adverse reactions between the two groups(5.26% vs 8.77%, P>0.05). Conclusion Amlodipine atorvastatin calcium is proven to be effective and can improve the blood pressure and blood lipid level and control the disease development.